{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:14:31Z","timestamp":1787238871536,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jaip.2018.05.032","type":"journal-article","created":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T10:51:01Z","timestamp":1528541461000},"page":"165-174.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Prevalence of Patients Eligible for Anti-IL-5 Treatment in a Cohort of Adult-Onset Asthma"],"prefix":"10.1016","volume":"7","author":[{"given":"Pinja","family":"Ilmarinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena E.","family":"Tuomisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onni","family":"Niemel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"Kankaanranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2018.05.032_bib1","doi-asserted-by":"crossref","first-page":"514868","DOI":"10.1155\/2015\/514868","article-title":"Phenotypes, risk factors and mechanisms of adult-onset asthma","volume":"2015","author":"Ilmarinen","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jaip.2018.05.032_bib2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jaip.2017.01.027","article-title":"Cluster analysis on longitudinal data of patients with adult-onset asthma","volume":"5","author":"Ilmarinen","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.05.032_bib3","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2018.05.032_bib4","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.05.032_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/bcpt.12163","article-title":"Eosinophil apoptosis as a therapeutic target in allergic asthma","volume":"114","author":"Ilmarinen","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jaip.2018.05.032_bib6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/1568010054526395","article-title":"Pharmacological regulation of human eosinophil apoptosis","volume":"4","author":"Kankaanranta","year":"2005","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"10.1016\/j.jaip.2018.05.032_bib7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.05.032_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.05.032_bib9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2018.05.032_bib10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.05.032_bib11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2018.05.032_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2018.05.032_bib13","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.05.032_bib14","doi-asserted-by":"crossref","first-page":"15042","DOI":"10.1038\/npjpcrm.2015.42","article-title":"Seinajoki Adult Asthma Study (SAAS): a protocol for a 12-year real-life follow-up study of new-onset asthma diagnosed at adult age and treated in primary and specialised care","volume":"25","author":"Kankaanranta","year":"2015","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.jaip.2018.05.032_bib15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/thx.2005.055699","article-title":"A\u00a010 year asthma programme in Finland: major change for the better","volume":"61","author":"Haahtela","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2018.05.032_bib16","first-page":"994","article-title":"Update on current care guidelines: asthma","volume":"129","author":"Haahtela","year":"2013","journal-title":"Duodecim"},{"key":"10.1016\/j.jaip.2018.05.032_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.rmed.2016.06.017","article-title":"A\u00a012-year prognosis of adult-onset asthma: Seinajoki Adult Asthma Study","volume":"117","author":"Tuomisto","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2018.05.032_bib18","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1183\/13993003.00850-2016","article-title":"The effect of smoking on lung function: a clinical study on adult-onset asthma","volume":"48","author":"Tommola","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2018.05.032_bib19","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1183\/13993003.02198-2015","article-title":"Co-morbidities and elevated IL-6 associate with negative outcome in adult-onset asthma","volume":"48","author":"Ilmarinen","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2018.05.032_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2018.05.032_bib21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/00949650701749356","article-title":"Interval estimation for a binomial proportion: a bootstrap approach","volume":"78","author":"Mantalos","year":"2008","journal-title":"J\u00a0Stat Comput Simul"},{"key":"10.1016\/j.jaip.2018.05.032_bib23","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","article-title":"Heterogeneity of phenotypes in severe asthmatics. The Belgian severe asthma registry (BSAR)","volume":"108","author":"Schleich","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2018.05.032_bib24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/02770903.2017.1322611","article-title":"Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study","volume":"55","author":"Albers","year":"2018","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2018.05.032_bib25","doi-asserted-by":"crossref","first-page":"00100","DOI":"10.1183\/23120541.00100-2015","article-title":"Clinical profile of patients with adult-onset eosinophilic asthma","volume":"2","author":"de Groot","year":"2016","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2018.05.032_bib26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2018.05.032_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.rmed.2016.12.017","article-title":"Severe and non-severe asthma in the community: a large electronic database analysis","volume":"123","author":"Varsano","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2018.05.032_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2003.10.041","article-title":"Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation","volume":"113","author":"Miranda","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.05.032_bib29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2018.05.032_bib30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1164\/ajrccm.156.3.9610046","article-title":"Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids","volume":"156","author":"Wenzel","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2018.05.032_bib31","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/j.1365-2222.2009.03319.x","article-title":"Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma","volume":"39","author":"Macedo","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.05.032_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12890-016-0263-8","article-title":"Burden of asthma with elevated blood eosinophil levels","volume":"16","author":"Casciano","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2018.05.032_bib33","doi-asserted-by":"crossref","first-page":"3690628","DOI":"10.1155\/2016\/3690628","article-title":"Emerging co-morbidities in adult asthma: risks, clinical associations and mechanisms","volume":"2016","author":"Kankaanranta","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jaip.2018.05.032_bib34","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1185\/03007990903218655","article-title":"Assessment of asthma control in primary care","volume":"25","author":"Mintz","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2018.05.032_bib35","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jaci.2007.03.022","article-title":"Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey","volume":"119","author":"Peters","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.05.032_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1185\/030079905X74925","article-title":"Assessment of asthma control in a general population of asthmatics","volume":"22","author":"Lenoir","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2018.05.032_bib37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1081\/JAS-200067000","article-title":"The status of asthma control and asthma prescribing practices in the United States: results of a large prospective asthma control survey of primary care practices","volume":"42","author":"Carlton","year":"2005","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2018.05.032_bib38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1513\/AnnalsATS.201308-264ED","article-title":"Multimorbidity: the new normal","volume":"10","author":"Lang","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2018.05.032_bib39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.anai.2016.10.028","article-title":"Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis","volume":"118","author":"Whittington","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2018.05.032_bib40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2018.05.032_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/cea.12853","article-title":"Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials","volume":"47","author":"Cabon","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.05.032_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pupt.2017.01.011","article-title":"Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils","volume":"43","author":"Brusselle","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaip.2018.05.032_bibE1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/00365518209168377","article-title":"Spirometric studies in non-smoking, healthy adults","volume":"159","author":"Viljanen","year":"1982","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"10.1016\/j.jaip.2018.05.032_bibE2","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2018.05.032_bibE3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","article-title":"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study","volume":"380","author":"Barnett","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.05.032_bibE4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1183\/13993003.02198-2015","article-title":"Co-morbidities and elevated IL-6 associate with negative outcome in adult-onset asthma","volume":"48","author":"Ilmarinen","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2018.05.032_bibE5","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0954-6111(98)90423-1","article-title":"Asthma health status measurement in clinical practice: validity of a new short and simple instrument","volume":"92","author":"Barley","year":"1998","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2018.05.032_bibE7","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/00949650701749356","article-title":"Interval estimation for a binomial proportion: a bootstrap approach","volume":"78","author":"Mantalos","year":"2008","journal-title":"J\u00a0Stat Comput Simul"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321981830388X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321981830388X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:18:00Z","timestamp":1761974280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221321981830388X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S221321981830388X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2018.05.032","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of Patients Eligible for Anti-IL-5 Treatment in a Cohort of Adult-Onset Asthma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2018.05.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}